The Amsterdam Pre-Exposure Project 2 (AMPrEP2)
Onderdeel van
Trefwoorden
Dit is de verlenging van AMPrEP. AMPrEP 2 zal doorgaan tot eind 2020 om data te verzamelen over long-term follow-up. In Nederland sterft er niemand meer aan aids of hiv. Toch krijgen er jaarlijks ongeveer 700 nieuwe mensen de diagnose hiv, resulterend in een levenslange chronische ziekte. Het medicijn PrEP kan infectie met dit virus voorkomen. Het Amsterdam PrEP-project (AMPrEP) onderzoekt sinds 2015 de toepasbaarheid van PrEP in de praktijk. De positieve uitkomsten hebben mede geleid tot een nationaal PrEP-programma.
Primary Objectives:
1. To assess the rate of switches of PrEP regimen by PrEP users (event-driven to daily and daily to event-driven), stop (defined as no PrEP use for 3 months or more) and re-start moments of PrEP use, and its determinants
2. To assess the HIV incidence rate among participants who use event-driven PrEP over the first 4 years of use
Secondary Objectives:
1. To assess changes in sexual behavior and compare these between daily and event-driven PrEP users over the first 4 years of use
2. To assess STI, including HCV, incidence and compare these between daily and event-driven PrEP users over the first 4 years of use
3. To assess the adherence to PrEP medication and compare these between daily and event-driven PrEP users over the first 4 years of use
4. To assess tenofovir disoproxil diphosphate levels in dried blood spots at seroconversion, and resistance patterns of breakthrough HIV infections among PrEP users
Looptijd: 1 juni 2018 - 1 december 2020